Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study.

Takiyama T, Kitsunai H, Maruyama F, Kitao N, Wakabayashi Y, Ito M, Kurihara H, Yamamoto C, Takeuchi J, Nanbu T, Abiko A, Homma R, Miyamoto Y, Yamagata K, Miyazaki A, Nakamura A, Nomoto H, Hokkaido-TZP Study Group

Open source

DOI: 10.1016/j.jdiacomp.2026.109391
Published: 2026 Aug 14
Container: Journal of diabetes and its complications
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jdiacomp.2026.109391,
  title = {Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study.},
  author = {Takiyama T and Kitsunai H and Maruyama F and Kitao N and Wakabayashi Y and Ito M and Kurihara H and Yamamoto C and Takeuchi J and Nanbu T and Abiko A and Homma R and Miyamoto Y and Yamagata K and Miyazaki A and Nakamura A and Nomoto H and Hokkaido-TZP Study Group},
  year = {2026},
  journal = {Journal of diabetes and its complications},
  doi = {10.1016/j.jdiacomp.2026.109391},
  url = {https://doi.org/10.1016/j.jdiacomp.2026.109391}
}

RIS

TY  - JOUR
TI  - Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study.
AU  - Takiyama T
AU  - Kitsunai H
AU  - Maruyama F
AU  - Kitao N
AU  - Wakabayashi Y
AU  - Ito M
AU  - Kurihara H
AU  - Yamamoto C
AU  - Takeuchi J
AU  - Nanbu T
AU  - Abiko A
AU  - Homma R
AU  - Miyamoto Y
AU  - Yamagata K
AU  - Miyazaki A
AU  - Nakamura A
AU  - Nomoto H
AU  - Hokkaido-TZP Study Group
PY  - 2026
JO  - Journal of diabetes and its complications
DO  - 10.1016/j.jdiacomp.2026.109391
UR  - https://doi.org/10.1016/j.jdiacomp.2026.109391
ER  -

APA

T, T., H, K., F, M., N, K., Y, W., M, I., H, K., C, Y., J, T., T, N., A, A., R, H., Y, M., K, Y., A, M., A, N., H, N., & Group, H. S. (2026). Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study.. Journal of diabetes and its complications. https://doi.org/10.1016/j.jdiacomp.2026.109391

Source records

pubmed · retrieved 2026-09-26T02:39:21.355Z